(NASDAQ: ATRA) Atara Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.94%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.33%.
Atara Biotherapeutics's earnings in 2026 is $32,688,000.On average, 6 Wall Street analysts forecast ATRA's earnings for 2026 to be -$9,426,094, with the lowest ATRA earnings forecast at -$11,621,100, and the highest ATRA earnings forecast at -$6,955,486. On average, 6 Wall Street analysts forecast ATRA's earnings for 2027 to be -$10,552,220, with the lowest ATRA earnings forecast at -$11,781,391, and the highest ATRA earnings forecast at -$9,102,241.
In 2028, ATRA is forecast to generate -$8,800,468 in earnings, with the lowest earnings forecast at -$11,941,682 and the highest earnings forecast at -$5,323,952.